Clinical and hemostatic responses to treatment in ventilator-associated pneumonia: Role of bacterial pathogens

Critical Care Medicine

Volumn 35, Issue 2, 2007, Pages 490-496

  El Solh, Ali A ^a,c   Choi, Goda ^b   Schultz, Marcus J ^b   Pineda, Lilibeth A ^a   Mankowski, Corey ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

Bronchoalveolar lavage; Hemostasis; Resolution; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CEFEPIME; PIPERACILLIN PLUS TAZOBACTAM; PROCOAGULANT; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL VIRULENCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; ESCHERICHIA COLI; FEMALE; HEMOSTASIS; HUMAN; INTENSIVE CARE UNIT; KINETICS; LUNG LAVAGE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

AGED; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES; PULMONARY ALVEOLI;

EID: 33846409051     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000253308.93761.09     Document Type: Article

References (40)

1. Ware L, Bastarache J, Wang L: Coagulation and fibrinolysis in human acute lung injury-New therapeutic targets? Keio J Med 2005; 54:142-149
2. Nishiuma T, Sisson TH, Subbotina N, et al: Localization of plasminogen activator activity within normal and injured lungs by in situ zymography. Am J Respir Cell Mol Biol 2004; 31:552-558
3. Levi M, van der Poll T, ten Cate H, et al: Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. Am J Respir Crit Care Med 1998; 158:92-98
4. Bertozzi P, Astedt B, Zenzius L, et al: Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322:890-897
5. Welty-Wolf KE, Carraway MS, Ortel TL, et al: Coagulation and inflammation in acute lung injury. Thromb Haemost 2002; 88:17-25
6. Schultz M, Haitsma J, Zhang H, et al: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia. Crit Care Med 2006; 34:871-877
7. Sueishi K, Nanno S, Tanaka K: Permeability enhancing and chemotactic activities of lower molecular weight degradation products of human fibrinogen. Thromb Haemost 1981; 45:90-94
8. Senior RM, Skogen WF, Griffin GL, et al: Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest 1986; 77: 1014-1019
9. Gunther A, Mosavi P, Heinemann S, et al: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-462
10. Schultz MJ, Millo J, Levi M, et al: Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59: 130-135
11. Choi G, Schultz MJ, van Till JW, et al: Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24:786-789
12. El Solh A, Okada M, Pietrantoni C, et al: Procoagulant and fibrinolytic activity in ventilator associated pneumonia: Impact of inadequate antimicrobial therapy. Intensive Care Medicine 2004; 30:1914-1920
13. Sabharwal AK, Bajaj SP, Ameri S, et al: Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med 1995; 151:758-767
14. Gando S, Kameue T, Matsuda N, et al: Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res 2003; 109:119-124
15. de Moerloose P, de Benedetti E, Nicod L, et al: Procoagulant activity in bronchoalveolar fluids: No relationship with tissue factor pathway inhibitor activity. Thromb Res 1992; 65:507-518
16. Luna C, Vujacich P, Niederman M, et al: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-685
17. Fagon JY, Chastre J, Hance AJ, et al: Detection of nosocomial lung infection in ventilated patients: Use of a protected specimen brush hand quantitative culture techniques in 147 patients. Am Rev Respir Dis 1998; 138:110-116
18. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829
19. Pugin J, Auckenthaler R, Mili N, et al: Diagnosis of ventilator- associated pneumonia by bacteriologic analysis of bronchoscopic and non-bronchoscopic blind bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143: 1121-1129
20. Bernard G, Artigas A, Brigham K, et al: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-824
21. Bone R, Sibbald W, Sprung C: The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101:1481-1483
22. Agusti C, Xaubet A, Luburich P, et al: Computed tomography-guided bronchoalveolar lavage in idiopathic pulmonary fibrosis. Thorax 1996; 51:841-845
23. El Solh A, Aquilina A, Dhillon R, et al: Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia. Am J Respir Crit Care Med 2002; 166: 1038-1043
24. de Moerloose P, Hamilton J, Sewell W, et al: Pertussigen in vivo enhances antigen specific production in vitro of lymphokine that stimulates macrophage procoagulant activity and plasminogen activator. J Immunol 1986; 137:3528-3533
25. Lyberg T, Nakstad B, Hetland O, et al: Procoagulant (thromboplastin) activity in human bronchoalveolar lavage fluids is derived from alveolar macrophages. Eur Respir J 1990; 3:61-67
26. van't Veer C, Mann K: Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 1997; 272: 4367-4377
27. Broze G, Girard T, Novotny W: Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29:7539-7546
28. Broze G: Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995; 6:S7-S13
29. Hartog CM, Wermelt JA, Sommerfeld CO, et al: Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med 2003; 167:593-598
30. Belaaouaj A, Li A, Wun T, et al: Matrix metalloproteinases cleave tissue factor pathway inhibitor. J Biol Chem 2000; 35:27123-27128
31. Rapaport S, Rao L: Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12:1111-1121
32. Rijneveld AW, Florquin S, Bresser P, et al: Plasminogen activator inhibitor type 1 deficiency does not Influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102:934-939
33. Sadikot R, Blackwell T, Christman J, et al: Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171:1209-1223
34. Garrard CS, A'Court CD: The diagnosis of pneumonia in the critically ill. Chest 1995; 108:17S-25S
35. Dennesen PJ, van der Ven AJ, Kessels AG, et al: Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163:1371-1375
36. Luna CM, Blanzaco D, Niederman MS, et al: Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31:676-682
37. Smith A, Fiel S, Mayer-Hamblett N, et al: Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: Lack of association in cystic fibrosis. Chest 2003; 123:1495-1502
38. Andrés M, Viejo-Diaz M, Pérez F, et al: Antibiotic tolerance induced by lactoferrin in clinical Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2005; 49:1613-1616
39. Chastre J, Wolff M, Fagon J, et al: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290:2588-2598
40. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia: Official statement of ATS and IDSA. Am J Respir Crit Care Med 2005; 171:388-416